Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate IDEAYA Biosciences, Inc. before investing.

In this article, we go over a few key elements for understanding IDEAYA Biosciences, Inc.’s stock price such as:

• IDEAYA Biosciences, Inc.’s current stock price and volume
• Why IDEAYA Biosciences, Inc.’s stock price changed recently
• Upgrades and downgrades for IDYA from analysts
• IDYA’s stock price momentum as measured by its relative strength

About IDEAYA Biosciences, Inc. (IDYA)

Before we jump into IDEAYA Biosciences, Inc.’s stock price, history, target price and what caused it to recently , let’s take a look at some background.

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate; and clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Want to learn more about IDEAYA Biosciences, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about IDEAYA Biosciences, Inc..

IDEAYA Biosciences, Inc.’s Stock Price as of Market Close

As of August 03, 2026, 4:00 PM, CST, IDEAYA Biosciences, Inc.’s stock price was $35.400.

IDEAYA Biosciences, Inc. is 0% from its previous closing price of $35.400.

During the last market session, IDEAYA Biosciences, Inc.’s stock traded between $34.560 and $35.990. Currently, there are approximately 88.70 million shares outstanding for IDEAYA Biosciences, Inc..

IDEAYA Biosciences, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

IDEAYA Biosciences, Inc. Stock Price History

IDEAYA Biosciences, Inc.’s (IDYA) price is currently down 0.28% so far this month.

During the month of August, IDEAYA Biosciences, Inc.’s stock price has reached a high of $35.990 and a low of $34.560.

Over the last year, IDEAYA Biosciences, Inc. has hit prices as high as $40.580 and as low as $22.090. Year to date, IDEAYA Biosciences, Inc.’s stock is up 2.4%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused IDEAYA Biosciences, Inc. Stock’s Price to ?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 03, 2026, there was 1 analyst who downgraded IDEAYA Biosciences, Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate IDEAYA Biosciences, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on IDEAYA Biosciences, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

IDEAYA Biosciences, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about IDEAYA Biosciences, Inc. (IDYA) by visiting AAII Stock Evaluator.

Relative Price Strength of IDEAYA Biosciences, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 03, 2026, IDEAYA Biosciences, Inc. has a weighted four-quarter relative price strength of 7.75%, which translates to a Momentum Score of 78 and is considered to be Strong.

Want to learn more about how IDEAYA Biosciences, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

IDEAYA Biosciences, Inc. Stock Price: Bottom Line

As of August 3, 2026, IDEAYA Biosciences, Inc.’s stock price is $35.400, which is 0% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like IDEAYA Biosciences, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.